A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia
| Status: | Completed |
|---|---|
| Conditions: | Anemia |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | February 2002 |
| End Date: | December 2005 |
A Randomized, Open-label Study of Dose Conversion Factors for Maintenance Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia
This study will determine the appropriate dose and frequency of administration of iv Mircera
maintenance therapy in hemodialysis patients with chronic renal anemia who were previously
receiving iv epoetin. The anticipated time on study treatment is 3-12 months and the target
sample size is <100 individuals.
maintenance therapy in hemodialysis patients with chronic renal anemia who were previously
receiving iv epoetin. The anticipated time on study treatment is 3-12 months and the target
sample size is <100 individuals.
Inclusion Criteria:
- adult patients >=18 years of age;
- chronic renal anemia;
- on hemodialysis therapy for at least 3 months;
- receiving iv epoetin alfa during the 2 weeks prior to the run-in period.
Exclusion Criteria:
- women who are pregnant, breastfeeding or using unreliable birth control methods;
- use of any investigational drug within 30 days of the run-in phase, or during the
run-in or study treatment period.
We found this trial at
13
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials